• Published On : Oct-2016 |
  • Pages : 131 Pages |
  • Format :

1. Executive Summary

2. Market Taxonomy

3. Global Hemoglobinopathy Market Analysis Scenario
   3.1. Pricing Analysis
        3.1.1. Pricing Assumptions
3.1.2. Price Analysis per Region
   3.2. Market Size (US$ Mn) and Forecast
        3.2.1. Market Size and Y-o-Y Growth
        3.2.2. Absolute $ Opportunity
   3.3. Market Overview
        3.3.1. Global Hemoglobinopathy Market Reimbursement Scenario

4. Market Dynamics
   4.1. Macro-economic Factors
   4.2. Drivers
        4.2.1. Supply Side
        4.2.2. Demand Side
   4.3. Restraints
   4.4. Opportunity
   4.5. Key Trends
   4.6. Forecast Factors – Relevance and Impact

5. Global Hemoglobinopathy Market Analysis and Forecasts, by Indication 
   5.1. Introduction
   5.2. Basis Point Share (BPS) Analysis by Indication 
   5.3. Y-o-Y Growth Projections by Indication 
   5.4. Market Value Forecast, 2016–2024
        5.4.1. Sickle Cell Disease
        5.4.2. Beta Thalassemia
        5.4.3. Alpha Thalassemia
   5.5. Market Attractiveness by Indication

6. Global Hemoglobinopathy Market Analysis and Forecasts, by End User 
   6.1. Introduction
   6.2. Basis Point Share (BPS) Analysis by End User 
   6.3. Y-o-Y Growth Projections by End User 
   6.4. Market Value Forecast by End User, 2016–2024
        6.4.1. Hospitals
        6.4.2. Diagnostics Laboratories
        6.4.3. Clinics
   6.5. Market Attractiveness by End User 

7. Global Hemoglobinopathy Market Analysis and Forecasts, by Test Type  
   7.1. Introduction
   7.2. Basis Point Share (BPS) Analysis by Test Type  
   7.3. Y-o-Y Growth Projections by Test Type  
   7.4. Market Value Forecast by Test Type, 2016–2024
        7.4.1. Routine Red Blood Cell (RBC) Count
        7.4.2. Genetic Testing
        7.4.3. Hemoglobin by High Performance Liquid Chromatography
        7.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
        7.4.5. Hemoglobin electrophoresis (Hb ELP)
        7.4.6. Hemoglobin Solubility Test
   7.5. Market Attractiveness by Test Type  

8. Global Hemoglobinopathy Market Analysis and Forecasts, by Region
   8.1. Basis Point Share (BPS) Analysis by Country
   8.2. Y-o-Y Growth Projections by Country
   8.3. Market Value Forecast by Region
        8.3.1. North America 
        8.3.2. Latin America 
        8.3.3. Europe 
        8.3.4. APAC 
        8.3.5. MEA 
   8.4. Market Attractiveness by Country

9. North America Hemoglobinopathy Market Analysis and Forecast
   9.1. Introduction
        9.1.1. Basis Point Share (BPS) Analysis by Country
        9.1.2. Y-o-Y Growth Projections by Country
        9.1.3. Key Findings
   9.2. Market Value Forecast by Indication, 2016–2024
        9.2.1. Sickle Cell Disease
        9.2.2. Beta Thalassemia
        9.2.3. Alpha Thalassemia
   9.3. Market Value Forecast by End User, 2016–2024
        9.3.1. Hospitals
        9.3.2. Diagnostics Labs
        9.3.3. Clinics
   9.4. Market Value Forecast by Test Type, 2016–2024
        9.4.1. Routine Red Blood Cell (RBC) Count
        9.4.2. Genetic Testing
        9.4.3. Hemoglobin by High Performance Liquid Chromatography
        9.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
        9.4.5. Hemoglobin electrophoresis (Hb ELP)
        9.4.6. Hemoglobin Solubility Test
   9.5. Market Value Forecast by Country, 2016–2024
        9.5.1. US
        9.5.2. Canada
   9.6. Market Attractiveness Analysis 
        9.6.1. by Indication
        9.6.2. by End User 
         9.6.3. by Test Type  
   9.7. Drivers and Restraints: Impact Analysis 

10. Latin America Hemoglobinopathy Market Analysis and Forecast
   10.1. Introduction
         10.1.1. Basis Point Share (BPS) Analysis by Country
         10.1.2. Y-o-Y Growth Projections by Country
         10.1.3. Key Findings
   10.2. Market Value Forecast by Indication, 2016–2024
         10.2.1. Sickle Cell Disease
         10.2.2. Beta Thalassemia
         10.2.3. Alpha Thalassemia
   10.3. Market Value Forecast by End User, 2016–2024
         10.3.1. Hospitals
         10.3.2. Diagnostics Labs
         10.3.3. Clinics
   10.4. Market Value Forecast by Test Type, 2016–2024
         10.4.1. Routine Red Blood Cell (RBC) Count
         10.4.2. Genetic Testing
         10.4.3. Hemoglobin by High Performance Liquid Chromatography
         10.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
         10.4.5. Hemoglobin electrophoresis (Hb ELP)
         10.4.6. Hemoglobin Solubility Test
   10.5. Market Value Forecast by Country, 2016–2024
         10.5.1. Argentina
         10.5.2. Brazil
         10.5.3. Mexico
         10.5.4. Rest of Latin America
   10.6. Market Attractiveness Analysis 
         10.6.1. by Indication
         10.6.2. by End User 
         10.6.3. by Test Type  
   10.7. Drivers and Restraints: Impact Analysis 

11. Europe Hemoglobinopathy Market Analysis and Forecast
   11.1. Introduction
         11.1.1. Basis Point Share (BPS) Analysis by Country
         11.1.2. Y-o-Y Growth Projections by Country
         11.1.3. Key Findings
   11.2. Market Value Forecast by Indication, 2016–2024
         11.2.1. Sickle Cell Disease
         11.2.2. Beta Thalassemia
         11.2.3. Alpha Thalassemia
   11.3. Market Value Forecast by End User, 2016–2024
         11.3.1. Hospitals
         11.3.2. Diagnostics Labs
         11.3.3. Clinics
   11.4. Market Value Forecast by Test Type, 2016–2024
         11.4.1. Routine Red Blood Cell (RBC) Count
         11.4.2. Genetic Testing
         11.4.3. Hemoglobin by High Performance Liquid Chromatography
         11.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
         11.4.5. Hemoglobin electrophoresis (Hb ELP)
         11.4.6. Hemoglobin Solubility Test
   11.5. Market Value Forecast by Country, 2016–2024
         11.5.1. Germany
         11.5.2. U.K.
         11.5.3. France
         11.5.4. Italy
         11.5.5. Spain
         11.5.6. Poland
         11.5.7. Russia
         11.5.8. Rest of Europe
   11.6. Market Attractiveness Analysis 
         11.6.1. by Indication
         11.6.2. by End User 
         11.6.3. by Test Type  
   11.7. Drivers and Restraints: Impact Analysis 

12. APAC Hemoglobinopathy Market Analysis and Forecast
   12.1. Introduction
         12.1.1. Basis Point Share (BPS) Analysis by Country
         12.1.2. Y-o-Y Growth Projections by Country
         12.1.3. Key Findings
   12.2. Market Value Forecast by Indication, 2016–2024
         12.2.1. Sickle Cell Disease
         12.2.2. Beta Thalassemia
         12.2.3. Alpha Thalassemia
   12.3. Market Value Forecast by End User, 2016–2024
         12.3.1. Hospitals
         12.3.2. Diagnostics Labs
         12.3.3. Clinics
   12.4. Market Value Forecast by Test Type, 2016–2024
         12.4.1. Routine Red Blood Cell (RBC) Count
         12.4.2. Genetic Testing
         12.4.3. Hemoglobin by High Performance Liquid Chromatography
         12.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
         12.4.5. Hemoglobin electrophoresis (Hb ELP)
         12.4.6. Hemoglobin Solubility Test
   12.5. Market Value Forecast by Country, 2016–2024
         12.5.1. China
         12.5.2. India
         12.5.3. Japan
         12.5.4. Australia 
         12.5.5. Rest of APAC
   12.6. Market Attractiveness Analysis 
        12.6.1. by Indication
        12.6.2. by End User 
        12.6.3. by Test Type  
   12.7. Drivers and Restraints: Impact Analysis 

13. MEA Hemoglobinopathy Market Analysis and Forecast
   13.1. Introduction
        13.1.1. Basis Point Share (BPS) Analysis by Country
        13.1.2. Y-o-Y Growth Projections by Country
        13.1.3. Key Findings
   13.2. Market Value Forecast by Indication, 2016–2024
        13.2.1. Sickle Cell Disease
        13.2.2. Beta Thalassemia
        13.2.3. Alpha Thalassemia
   13.3. Market Value Forecast by End User, 2016–2024
        13.3.1. Hospitals
        13.3.2. Diagnostics Labs
        13.3.3. Clinics
   13.4. Market Value Forecast by Test Type, 2016–2024
        13.4.1. Routine Red Blood Cell (RBC) Count
        13.4.2. Genetic Testing
        13.4.3. Hemoglobin by High Performance Liquid Chromatography
        13.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
        13.4.5. Hemoglobin electrophoresis (Hb ELP)
        13.4.6. Hemoglobin Solubility Test
   13.5. Market Value Forecast by Country, 2016–2024
        13.5.1. GCC Countries
        13.5.2. South Africa
        13.5.3. Rest of MEA
   13.6. Market Attractiveness Analysis 
        13.6.1. by Indication
        13.6.2. by End User 
        13.6.3. by Test Type  
   13.7. Drivers and Restraints: Impact Analysis 

14. Competition Landscape
   14.1. Competition Dashboard
   14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
        14.2.1. Abbott Diagnostics
        14.2.2. Bio-Rad Laboratories, Inc.
        14.2.3. Danaher Corp.
        14.2.4. Mindray Medical International Ltd
        14.2.5. Nexcelom Bioscience LLC.
        14.2.6. Nihon Kohden Europe Ltd
        14.2.7. PerkinElmer Inc.
        14.2.8. Siemens Healthineers
        14.2.9. Sysmex Europe GmbH

15. Assumptions and Acronyms Used

16. Research Methodology


List of Tables

Table 01: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 02: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 03: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 04: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Region, 2015–2024
Table 05: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 06: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 07: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 08: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 09: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 10: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 11: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 12: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 13: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 14: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 15: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 16: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 17: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 18: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 19: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 20: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024
Table 21: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2024
Table 22: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2024
Table 23: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2024
Table 24: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015–2024


List of Figures

Figure 01: Routine Red Blood Cell (RBC) Count Test Pricing Difference (US$) By Region, 2015 A
Figure 02: Genetic Testing Pricing Difference (US$) By Region, 2015 A
Figure 03: Hemoglobin by high performance liquid chromatography (HPLC) Test Pricing Difference (US$) By Region, 2015 A
Figure 04: Hemoglobin isoelectric focusing (Hb IEF) Pricing Difference (US$) By Region, 2015 A
Figure 05: Hemoglobin electrophoresis (Hb ELP) Test Pricing Difference (US$) By Region, 2015 A
Figure 06: Hemoglobin solubility test (SST) Pricing Difference (US$) By Region, 2015 A
Figure 07: Global Hemoglobinopathy Market Value (US$ Mn) Forecast, 2016–2024
Figure 08 : Global Hemoglobinopathy Market Absolute $ Opportunity (US$ Mn), 2016–2024
Figure 09: Global Hemoglobinopathy Market Share and BPS Analysis (%) By Indication, 2016 & 2024
Figure 10: Global Hemoglobinopathy Y-o-Y growth (%) By Indication, 2016–2024
Figure 11: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Sickle Cell Disease Segment, 2015–2024
Figure 12: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Beta Thalassemia Segment, 2015–2024
Figure 13: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Alpha Thalassemia Segment, 2015–2024
Figure 14: Global Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 15: Global Hemoglobinopathy Market Share and BPS Analysis (%) By End User, 2016 & 2024
Figure 16: Global Hemoglobinopathy Y-o-Y growth (%) By End User, 2016–2024
Figure 17: Global Hemoglobinopathy Market Absolute $ Opportunity By Hospitals Segment, 2016–2024
Figure 18: Global Hemoglobinopathy Market Absolute $ Opportunity By Diagnostics Laboratories Segment, 2016–2024
Figure 19: Global Hemoglobinopathy Market Absolute $ Opportunity By Clinics Segment, 2016–2024
Figure 20: Global Hemoglobinopathy Market Attractiveness Analysis By End-user, 2016–2024
Figure 21: Hemoglobinopathy Market Share Analysis (%) By Test Type, 2016 & 2024
Figure 22: Global Hemoglobinopathy Y-o-Y growth (%) By Test Type, 2016–2024
Figure 23: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By RBC Count, 2015–2024
Figure 24: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Genetic Testing, 2015–2024
Figure 25: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin HPLC, 2015–2024
Figure 26: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Isoelectric Focusing, 2015–2024
Figure 27: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Electrophoresis, 2015–2024
Figure 28: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Solubility Test, 2015–2024
Figure 29: Global Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 30: Global Hemoglobinopathy Market Value (US$ Mn) and CAGR (%) By Region, 2015, 2020, and 2024
Figure 31: Global Hemoglobinopathy Market Share Analysis (%) By Region, 2016 & 2024
Figure 32: Global Hemoglobinopathy Y-o-Y growth (%) By Region, 2016–2024
Figure 33: North America Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 34: Latin America Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 35: Europe Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 36: APAC Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 37: MEA Hemoglobinopathy Market Absolute $ Opportunity, 2016–2024
Figure 38: Global Hemoglobinopathy Market Attractiveness Analysis By Region, 2016–2024
Figure 39: North America Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 40: North America Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 41: North America Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 42: North America Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 43: North America Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
Figure 44: Latin America Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 45: Latin America Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 46: Latin America Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 47: Latin America Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 48: Latin America Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
Figure 49: Europe Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 50: Europe Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 51: Europe Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 52: Europe Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 53: Europe Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
Figure 54: Asia Pacific Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 55: Asia Pacific Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 56: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 57: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 58: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024
Figure 59: Middle East & Africa Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 60: Middle East & Africa Hemoglobinopathy Y-o-Y growth (%) By Country, 2016–2024
Figure 61: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By Indication, 2016–2024
Figure 62: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By End User, 2016–2024
Figure 63: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By Test Type, 2016–2024